Objective
=========

To study effects and side effects of gemcitabine (2\',2\'-difluorodeoxycytidine, dFdC), a pyrimidine synthesis inhibitor, on skin lesions of a herpes simplex virus-induced Behçet\'s disease (BD)-like mouse model.

Methods
=======

Dose-escalation studies with dFdC were performed in ICR mice with intraperitoneal application over 5 days. After inoculation of ICR mice with herpes simplex virus and classification as having BD according to a revised Japanese classification, 18 BD-mice were randomly assigned to placebo, 0.06 or 0.12 μg of dFdC/day over 5 days. Serum levels of interleukin (IL)-4, IL-6, IL-10, tumor necrosis factor-α and interferon-γ were determined using ELISA assays.

Results
=======

After application of 3 μg dFdC over 5 days, alanine aminotransferase increased (*P*= 0.032) but all other kidney and liver parameters were unchanged. In BD mice, 5 days of dFdC treatment with 0.06 or 0.12 μg of dFdC/day resulted in a dose-dependent improvement in cutaneous manifestations by more than 60% (*P*= 0.017). There was no significant change in cytokine levels and none of the cytokine levels correlated with response to treatment.

Conclusion
==========

DFdC shows promising effects to improve cutaneous lesions in the herpes simplex virus-induced BD-like mouse model. In this animal model, effects of dFdC on the cytokine profile remained inconclusive.
